Skip to content
Screener

Regenxbio RGNX Gross Profit

Discontinued — last reported Q4 '24

Gross Profit at other companies

Biogen logo
BiogenBIIB
$1.96B-4.0%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$786.91M+16.5%
Opko Health logo
Opko HealthOPK
$80.02M+62.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$228.63M+114%

Other financials

Income statement

See full
Revenue$108.0M+406%
Operating income$29.3M+146%
Net income$22.7M+132%
EPS (diluted)$0.43+131%

Balance sheet

See full
Cash & equivalents$36.5M-54.1%
Total debt$69.0M-11.3%
Total equity$71.8M-66.4%
Total assets$386.6M-33.5%

Cash flow

See full
Operating cash flow-$62.2M-26.1%
CapEx$760.0K+94.4%
Free cash flow-$63.0M-26.7%

Valuation

See full
Market cap$707.66M+87.8%
Enterprise value$740.13M+97.4%
P/S4.1×+1.6×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-94.1%-9.3pp
Net margin-112.6%-0.1pp
FCF margin-143.1%-456pp

Returns & leverage

See full
Return on equity-137.6%-817pp
Debt / equity+0.6×
Current ratio2.9×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

The source filing: Regenxbio’s 10-K, filed March 5, 2026. Open the filing →

Filed
Mar 5, 2026, 4:21 PM EST
Fiscal year
FY2025
Accession
0001193125-26-094013

FAQ

What is Regenxbio's gross profit?
Regenxbio (RGNX) reported gross profit of $14.9M in Q4 2024.
How has Regenxbio's gross profit changed year-over-year?
Regenxbio's gross profit increased by 35.7% year-over-year, from $10.98M to $14.9M.
What is the long-term trend for Regenxbio's gross profit?
Over 3 years (2021 to 2024), Regenxbio's gross profit has grown at a -50.8% compound annual growth rate (CAGR), from $418.51M to $49.76M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.

Ask your AI about Regenxbio's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude